Investors & Media

Philina brings more than 15 years of biopharmaceutical industry leadership experience, with a strong track record of product commercialization and successfully building high growth organizations while fostering a strong company culture. Since April 2022, Philina has served as Chief Commercial Officer of Blueprint Medicines. She joined Blueprint Medicines in August 2014 as Senior Director, New Product Strategy and Development and subsequently held multiple commercial roles with responsibility for strategy, operations, patient services, marketing and the precision medicine field team. During her tenure, she has been instrumental in building the company's portfolio from research-stage onwards, laying the groundwork for the commercial strategy that is driving the successful launches of AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib). From January 2021 to April 2022, she served as Senior Vice President, Head of Portfolio Strategy and Program Management, where she was responsible for providing strategic and operational leadership across the company's portfolio. Previously, Philina held product strategy and marketing roles of increasing responsibility at Algeta, Sanofi and Genzyme. She serves on the board of Fusion Pharmaceuticals, as a member of both the Nomination and Governance committee and Research and Development committee. Philina earned a B.S. in Biochemistry from the University of Alberta, and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology.